| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 160 | 2026 | 2049 | 17.450 |
Why?
|
| Anti-HIV Agents | 32 | 2026 | 345 | 4.680 |
Why?
|
| Patient Compliance | 24 | 2018 | 463 | 4.010 |
Why?
|
| Medication Adherence | 21 | 2026 | 338 | 3.880 |
Why?
|
| Patient Acceptance of Health Care | 23 | 2026 | 512 | 3.280 |
Why?
|
| Antiretroviral Therapy, Highly Active | 28 | 2015 | 256 | 2.820 |
Why?
|
| Viral Load | 23 | 2020 | 416 | 2.750 |
Why?
|
| Mass Screening | 19 | 2022 | 822 | 2.540 |
Why?
|
| Anti-Retroviral Agents | 12 | 2025 | 155 | 2.450 |
Why?
|
| Continuity of Patient Care | 9 | 2018 | 143 | 2.390 |
Why?
|
| Health Services Accessibility | 15 | 2019 | 712 | 2.350 |
Why?
|
| AIDS Serodiagnosis | 9 | 2019 | 52 | 2.240 |
Why?
|
| Patient-Centered Care | 8 | 2020 | 236 | 2.180 |
Why?
|
| Physician-Patient Relations | 9 | 2018 | 441 | 2.020 |
Why?
|
| Trust | 7 | 2017 | 91 | 1.850 |
Why?
|
| Drug Monitoring | 8 | 2025 | 292 | 1.810 |
Why?
|
| Adult | 120 | 2026 | 31282 | 1.810 |
Why?
|
| Delivery of Health Care | 13 | 2020 | 689 | 1.760 |
Why?
|
| HIV | 9 | 2024 | 174 | 1.620 |
Why?
|
| Health Knowledge, Attitudes, Practice | 15 | 2018 | 919 | 1.590 |
Why?
|
| Middle Aged | 102 | 2026 | 28601 | 1.580 |
Why?
|
| Texas | 39 | 2025 | 3686 | 1.570 |
Why?
|
| Primary Health Care | 12 | 2019 | 775 | 1.540 |
Why?
|
| Male | 143 | 2026 | 64957 | 1.480 |
Why?
|
| CD4 Lymphocyte Count | 22 | 2019 | 227 | 1.460 |
Why?
|
| Hospitalization | 9 | 2019 | 1950 | 1.410 |
Why?
|
| HIV Seropositivity | 5 | 2012 | 123 | 1.400 |
Why?
|
| Patient Satisfaction | 4 | 2017 | 464 | 1.350 |
Why?
|
| Health Promotion | 5 | 2017 | 422 | 1.330 |
Why?
|
| Female | 129 | 2026 | 70963 | 1.320 |
Why?
|
| Humans | 188 | 2026 | 131163 | 1.310 |
Why?
|
| Young Adult | 46 | 2020 | 10103 | 1.280 |
Why?
|
| Ambulatory Care Facilities | 11 | 2022 | 231 | 1.200 |
Why?
|
| Veterans | 17 | 2026 | 1763 | 1.190 |
Why?
|
| Cross-Sectional Studies | 23 | 2025 | 3829 | 1.170 |
Why?
|
| Community Health Centers | 4 | 2014 | 35 | 1.120 |
Why?
|
| Sexual Behavior | 5 | 2020 | 232 | 1.110 |
Why?
|
| Anemia, Sickle Cell | 4 | 2013 | 334 | 1.100 |
Why?
|
| Risk-Taking | 3 | 2020 | 96 | 1.090 |
Why?
|
| United States | 56 | 2025 | 12072 | 1.080 |
Why?
|
| Physicians | 6 | 2022 | 635 | 1.080 |
Why?
|
| Ambulatory Care | 6 | 2015 | 401 | 1.030 |
Why?
|
| Social Support | 5 | 2020 | 370 | 1.020 |
Why?
|
| Child Health Services | 3 | 2013 | 88 | 1.000 |
Why?
|
| HIV-1 | 9 | 2026 | 490 | 0.950 |
Why?
|
| Disease Transmission, Infectious | 2 | 2018 | 71 | 0.940 |
Why?
|
| Surveys and Questionnaires | 17 | 2025 | 4066 | 0.940 |
Why?
|
| Healthcare Disparities | 5 | 2024 | 523 | 0.930 |
Why?
|
| Medicare | 5 | 2024 | 442 | 0.930 |
Why?
|
| Telemedicine | 6 | 2026 | 526 | 0.930 |
Why?
|
| Peer Group | 3 | 2018 | 128 | 0.900 |
Why?
|
| Hepatitis C | 11 | 2010 | 381 | 0.890 |
Why?
|
| Cohort Studies | 36 | 2023 | 5063 | 0.860 |
Why?
|
| Homosexuality, Male | 7 | 2020 | 58 | 0.850 |
Why?
|
| Serologic Tests | 3 | 2020 | 122 | 0.850 |
Why?
|
| Communication | 5 | 2022 | 543 | 0.830 |
Why?
|
| Adolescent | 46 | 2020 | 20987 | 0.830 |
Why?
|
| Drug Prescriptions | 2 | 2024 | 237 | 0.820 |
Why?
|
| Physicians, Primary Care | 2 | 2016 | 100 | 0.820 |
Why?
|
| Quality of Health Care | 3 | 2013 | 413 | 0.770 |
Why?
|
| Smoking Cessation | 4 | 2026 | 191 | 0.740 |
Why?
|
| Sexual and Gender Minorities | 2 | 2020 | 67 | 0.720 |
Why?
|
| Behavior Therapy | 6 | 2026 | 273 | 0.700 |
Why?
|
| Pre-Exposure Prophylaxis | 3 | 2019 | 46 | 0.700 |
Why?
|
| Appointments and Schedules | 5 | 2015 | 53 | 0.690 |
Why?
|
| Health Care Surveys | 7 | 2016 | 276 | 0.660 |
Why?
|
| Prospective Studies | 17 | 2023 | 6459 | 0.660 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 1295 | 0.650 |
Why?
|
| Survivors | 2 | 2015 | 344 | 0.650 |
Why?
|
| Text Messaging | 2 | 2019 | 42 | 0.650 |
Why?
|
| Health Services Needs and Demand | 4 | 2019 | 179 | 0.640 |
Why?
|
| Substance-Related Disorders | 4 | 2021 | 496 | 0.630 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2020 | 37 | 0.620 |
Why?
|
| Aged | 37 | 2024 | 21025 | 0.610 |
Why?
|
| Chronic Disease | 2 | 2015 | 1246 | 0.610 |
Why?
|
| Insurance, Health | 2 | 2018 | 146 | 0.590 |
Why?
|
| Soft Tissue Infections | 1 | 2020 | 90 | 0.580 |
Why?
|
| Patient Participation | 2 | 2019 | 254 | 0.570 |
Why?
|
| Early Medical Intervention | 2 | 2016 | 32 | 0.560 |
Why?
|
| Community-Acquired Infections | 2 | 2020 | 254 | 0.550 |
Why?
|
| Health Services | 2 | 2015 | 69 | 0.550 |
Why?
|
| Interviews as Topic | 7 | 2026 | 466 | 0.550 |
Why?
|
| Internal Medicine | 2 | 2023 | 124 | 0.550 |
Why?
|
| Attitude to Health | 5 | 2018 | 247 | 0.550 |
Why?
|
| Dementia | 1 | 2023 | 436 | 0.540 |
Why?
|
| Unsafe Sex | 1 | 2017 | 23 | 0.530 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2020 | 235 | 0.530 |
Why?
|
| Office Visits | 2 | 2019 | 80 | 0.520 |
Why?
|
| Patient Outcome Assessment | 2 | 2022 | 89 | 0.510 |
Why?
|
| Community Health Workers | 4 | 2015 | 87 | 0.510 |
Why?
|
| Patient Selection | 3 | 2017 | 729 | 0.510 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2015 | 262 | 0.510 |
Why?
|
| Mentors | 3 | 2016 | 170 | 0.500 |
Why?
|
| Hospitals, Pediatric | 2 | 2013 | 808 | 0.500 |
Why?
|
| Cognition | 1 | 2022 | 829 | 0.500 |
Why?
|
| Counseling | 1 | 2018 | 238 | 0.490 |
Why?
|
| Retrospective Studies | 40 | 2025 | 17753 | 0.480 |
Why?
|
| Program Evaluation | 6 | 2019 | 447 | 0.470 |
Why?
|
| Hospitals, Veterans | 3 | 2017 | 336 | 0.460 |
Why?
|
| Health Personnel | 3 | 2025 | 541 | 0.450 |
Why?
|
| Guideline Adherence | 2 | 2018 | 387 | 0.450 |
Why?
|
| Sickness Impact Profile | 1 | 2015 | 38 | 0.450 |
Why?
|
| Socioeconomic Factors | 7 | 2015 | 915 | 0.450 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 878 | 0.450 |
Why?
|
| Anxiety | 4 | 2026 | 1014 | 0.440 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 789 | 0.440 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2011 | 32 | 0.440 |
Why?
|
| Sleep Wake Disorders | 4 | 2025 | 204 | 0.440 |
Why?
|
| Community Health Services | 3 | 2018 | 86 | 0.430 |
Why?
|
| Health Education | 3 | 2015 | 228 | 0.420 |
Why?
|
| Qualitative Research | 8 | 2026 | 730 | 0.420 |
Why?
|
| Veterans Health | 1 | 2016 | 170 | 0.420 |
Why?
|
| Communication Barriers | 1 | 2014 | 47 | 0.420 |
Why?
|
| Psychometrics | 2 | 2015 | 678 | 0.410 |
Why?
|
| Urban Population | 6 | 2023 | 287 | 0.410 |
Why?
|
| Marketing of Health Services | 1 | 2014 | 25 | 0.410 |
Why?
|
| Reminder Systems | 2 | 2011 | 62 | 0.410 |
Why?
|
| Emergency Service, Hospital | 6 | 2018 | 1224 | 0.400 |
Why?
|
| Role | 1 | 2013 | 27 | 0.400 |
Why?
|
| Depression | 7 | 2026 | 1320 | 0.400 |
Why?
|
| Protease Inhibitors | 2 | 2015 | 95 | 0.390 |
Why?
|
| Inpatients | 3 | 2023 | 562 | 0.380 |
Why?
|
| Social Marketing | 1 | 2013 | 9 | 0.380 |
Why?
|
| Pilot Projects | 7 | 2026 | 1445 | 0.370 |
Why?
|
| Public Health | 2 | 2016 | 269 | 0.370 |
Why?
|
| Risk Factors | 18 | 2022 | 11074 | 0.360 |
Why?
|
| Internship and Residency | 2 | 2023 | 1223 | 0.360 |
Why?
|
| Patient Preference | 1 | 2014 | 151 | 0.360 |
Why?
|
| Multivariate Analysis | 9 | 2015 | 1378 | 0.360 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 163 | 0.360 |
Why?
|
| Hospitals, Urban | 2 | 2015 | 97 | 0.360 |
Why?
|
| Pain | 3 | 2025 | 450 | 0.350 |
Why?
|
| Syphilis, Cutaneous | 1 | 2011 | 4 | 0.350 |
Why?
|
| Quality of Life | 4 | 2015 | 2082 | 0.340 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 131 | 0.340 |
Why?
|
| Skin Ulcer | 1 | 2011 | 32 | 0.340 |
Why?
|
| Hospitals, General | 1 | 2011 | 25 | 0.340 |
Why?
|
| Anus Neoplasms | 4 | 2015 | 40 | 0.330 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 2010 | 4 | 0.330 |
Why?
|
| Alcohol Drinking | 2 | 2026 | 341 | 0.330 |
Why?
|
| Parent-Child Relations | 1 | 2013 | 253 | 0.330 |
Why?
|
| Language | 1 | 2013 | 219 | 0.330 |
Why?
|
| Lost to Follow-Up | 3 | 2022 | 32 | 0.330 |
Why?
|
| Poverty | 3 | 2015 | 462 | 0.330 |
Why?
|
| Syphilis | 1 | 2011 | 96 | 0.320 |
Why?
|
| Interpersonal Relations | 1 | 2012 | 223 | 0.320 |
Why?
|
| Attitude of Health Personnel | 4 | 2025 | 707 | 0.320 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2010 | 13 | 0.320 |
Why?
|
| Motivation | 1 | 2013 | 328 | 0.320 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 141 | 0.320 |
Why?
|
| Time Factors | 9 | 2018 | 6196 | 0.310 |
Why?
|
| Communications Media | 1 | 2010 | 5 | 0.310 |
Why?
|
| Pain Measurement | 4 | 2014 | 353 | 0.310 |
Why?
|
| Vascular Diseases | 1 | 2011 | 146 | 0.300 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 2904 | 0.300 |
Why?
|
| Itraconazole | 1 | 2009 | 24 | 0.300 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2009 | 982 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 1267 | 0.290 |
Why?
|
| Sierra Leone | 4 | 2018 | 19 | 0.290 |
Why?
|
| Self Administration | 2 | 2011 | 49 | 0.290 |
Why?
|
| Treatment Outcome | 14 | 2016 | 12936 | 0.290 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2015 | 514 | 0.290 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 352 | 0.290 |
Why?
|
| Histoplasmosis | 1 | 2009 | 55 | 0.280 |
Why?
|
| Electronic Health Records | 4 | 2024 | 844 | 0.280 |
Why?
|
| Regression Analysis | 4 | 2015 | 761 | 0.280 |
Why?
|
| Alcoholism | 2 | 2023 | 244 | 0.270 |
Why?
|
| Liver Neoplasms | 3 | 2009 | 1373 | 0.260 |
Why?
|
| Cholangiocarcinoma | 1 | 2009 | 126 | 0.260 |
Why?
|
| Bile Duct Neoplasms | 1 | 2009 | 130 | 0.260 |
Why?
|
| Self Efficacy | 3 | 2013 | 211 | 0.250 |
Why?
|
| Health Plan Implementation | 2 | 2018 | 39 | 0.240 |
Why?
|
| Patient Education as Topic | 4 | 2019 | 464 | 0.240 |
Why?
|
| Glycerophospholipids | 1 | 2026 | 13 | 0.240 |
Why?
|
| Databases, Factual | 1 | 2011 | 1240 | 0.240 |
Why?
|
| Public Health Practice | 2 | 2016 | 20 | 0.230 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 214 | 0.230 |
Why?
|
| Prevalence | 8 | 2015 | 2701 | 0.230 |
Why?
|
| Self Report | 3 | 2021 | 554 | 0.230 |
Why?
|
| Logistic Models | 4 | 2015 | 1797 | 0.220 |
Why?
|
| Prisoners | 4 | 2010 | 38 | 0.220 |
Why?
|
| Neuropsychological Tests | 3 | 2023 | 960 | 0.220 |
Why?
|
| Internet | 1 | 2007 | 420 | 0.210 |
Why?
|
| Thyroid Neoplasms | 1 | 2007 | 241 | 0.210 |
Why?
|
| Infant | 9 | 2015 | 13352 | 0.210 |
Why?
|
| Patient Care | 2 | 2016 | 98 | 0.210 |
Why?
|
| Rilpivirine | 1 | 2023 | 5 | 0.200 |
Why?
|
| Pediatrics | 1 | 2013 | 1252 | 0.200 |
Why?
|
| Drug Substitution | 1 | 2023 | 27 | 0.200 |
Why?
|
| Eosinophilia | 2 | 2014 | 112 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2015 | 750 | 0.190 |
Why?
|
| Smoking | 2 | 2025 | 932 | 0.190 |
Why?
|
| Teaching Rounds | 1 | 2023 | 30 | 0.190 |
Why?
|
| Cell Phone | 2 | 2014 | 33 | 0.190 |
Why?
|
| Creativity | 1 | 2022 | 12 | 0.190 |
Why?
|
| Child, Preschool | 7 | 2015 | 15110 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 740 | 0.180 |
Why?
|
| Mobile Applications | 1 | 2024 | 114 | 0.180 |
Why?
|
| Pyridones | 1 | 2023 | 140 | 0.180 |
Why?
|
| Parents | 3 | 2015 | 1128 | 0.180 |
Why?
|
| Survival Analysis | 5 | 2009 | 1483 | 0.180 |
Why?
|
| Executive Function | 1 | 2022 | 122 | 0.170 |
Why?
|
| HIV Antibodies | 2 | 2022 | 71 | 0.170 |
Why?
|
| Health Policy | 2 | 2014 | 234 | 0.170 |
Why?
|
| Liver Cirrhosis | 3 | 2007 | 903 | 0.170 |
Why?
|
| Culture | 2 | 2012 | 70 | 0.170 |
Why?
|
| Child | 9 | 2016 | 26341 | 0.170 |
Why?
|
| Staphylococcus aureus | 2 | 2020 | 483 | 0.170 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 1490 | 0.160 |
Why?
|
| Rural Population | 1 | 2023 | 276 | 0.160 |
Why?
|
| Trypanosoma cruzi | 1 | 2024 | 256 | 0.160 |
Why?
|
| Mentoring | 1 | 2022 | 85 | 0.160 |
Why?
|
| Housing | 1 | 2020 | 74 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 1129 | 0.160 |
Why?
|
| Emigrants and Immigrants | 2 | 2013 | 169 | 0.160 |
Why?
|
| Early Diagnosis | 2 | 2014 | 195 | 0.150 |
Why?
|
| Prisons | 2 | 2010 | 15 | 0.150 |
Why?
|
| Chagas Disease | 1 | 2024 | 320 | 0.150 |
Why?
|
| Memory Disorders | 1 | 2021 | 204 | 0.150 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2003 | 430 | 0.150 |
Why?
|
| Risk Assessment | 5 | 2015 | 3711 | 0.150 |
Why?
|
| Social Stigma | 1 | 2020 | 82 | 0.150 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 6797 | 0.150 |
Why?
|
| Incidence | 9 | 2015 | 3360 | 0.150 |
Why?
|
| House Calls | 1 | 2018 | 35 | 0.140 |
Why?
|
| Drug Therapy, Combination | 3 | 2011 | 1173 | 0.140 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 830 | 0.140 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 5196 | 0.140 |
Why?
|
| Chicago | 1 | 2018 | 22 | 0.140 |
Why?
|
| Patients | 1 | 2019 | 122 | 0.140 |
Why?
|
| Linear Models | 2 | 2013 | 688 | 0.140 |
Why?
|
| HIV Core Protein p24 | 1 | 2018 | 10 | 0.140 |
Why?
|
| Case-Control Studies | 5 | 2018 | 3359 | 0.140 |
Why?
|
| HIV Serosorting | 1 | 2017 | 1 | 0.130 |
Why?
|
| Intention | 3 | 2013 | 105 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 2085 | 0.130 |
Why?
|
| Condoms | 1 | 2017 | 49 | 0.130 |
Why?
|
| Health Communication | 1 | 2018 | 30 | 0.130 |
Why?
|
| Minority Health | 1 | 2017 | 12 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2003 | 550 | 0.130 |
Why?
|
| Affect | 2 | 2025 | 159 | 0.130 |
Why?
|
| Factor Analysis, Statistical | 2 | 2015 | 237 | 0.130 |
Why?
|
| Mental Health | 1 | 2021 | 378 | 0.130 |
Why?
|
| Sexual Partners | 1 | 2017 | 80 | 0.130 |
Why?
|
| Waiting Lists | 1 | 2019 | 253 | 0.130 |
Why?
|
| Minority Groups | 2 | 2013 | 260 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 198 | 0.120 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 86 | 0.120 |
Why?
|
| Perception | 1 | 2018 | 231 | 0.120 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 210 | 0.120 |
Why?
|
| Risk | 2 | 2009 | 726 | 0.120 |
Why?
|
| Antiviral Agents | 3 | 2010 | 807 | 0.110 |
Why?
|
| Sex Factors | 3 | 2010 | 1356 | 0.110 |
Why?
|
| Self-Assessment | 1 | 2015 | 58 | 0.110 |
Why?
|
| Feasibility Studies | 3 | 2026 | 824 | 0.110 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 151 | 0.110 |
Why?
|
| Survival Rate | 3 | 2010 | 2114 | 0.110 |
Why?
|
| Liver Diseases | 3 | 2007 | 385 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 1545 | 0.110 |
Why?
|
| Cities | 1 | 2014 | 51 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2005 | 134 | 0.100 |
Why?
|
| Splints | 1 | 2013 | 11 | 0.100 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2025 | 729 | 0.100 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2014 | 77 | 0.100 |
Why?
|
| Hepacivirus | 3 | 2010 | 273 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 2 | 2010 | 356 | 0.100 |
Why?
|
| Visual Analog Scale | 1 | 2013 | 8 | 0.100 |
Why?
|
| Professional-Patient Relations | 1 | 2014 | 92 | 0.100 |
Why?
|
| Patient Advocacy | 1 | 2013 | 60 | 0.100 |
Why?
|
| Neuralgia | 1 | 2013 | 48 | 0.100 |
Why?
|
| Failure to Thrive | 1 | 2013 | 86 | 0.100 |
Why?
|
| Proof of Concept Study | 2 | 2026 | 40 | 0.100 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 130 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 2596 | 0.090 |
Why?
|
| Violence | 1 | 2013 | 129 | 0.090 |
Why?
|
| Centralized Hospital Services | 1 | 2012 | 5 | 0.090 |
Why?
|
| Emtricitabine | 1 | 2012 | 3 | 0.090 |
Why?
|
| Homosexuality | 2 | 2010 | 11 | 0.090 |
Why?
|
| Organophosphonates | 1 | 2012 | 21 | 0.090 |
Why?
|
| Benzoxazines | 1 | 2012 | 23 | 0.090 |
Why?
|
| Tenofovir | 1 | 2012 | 24 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 431 | 0.090 |
Why?
|
| Alkynes | 1 | 2012 | 27 | 0.090 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2009 | 88 | 0.090 |
Why?
|
| Cyclopropanes | 1 | 2012 | 70 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2012 | 80 | 0.090 |
Why?
|
| Spouses | 1 | 2012 | 70 | 0.090 |
Why?
|
| Health Surveys | 1 | 2013 | 261 | 0.090 |
Why?
|
| Stereotyping | 1 | 2011 | 19 | 0.090 |
Why?
|
| Motivational Interviewing | 1 | 2012 | 51 | 0.090 |
Why?
|
| Child, Exceptional | 1 | 2011 | 3 | 0.090 |
Why?
|
| Disease Progression | 3 | 2019 | 2200 | 0.090 |
Why?
|
| ROC Curve | 1 | 2013 | 613 | 0.090 |
Why?
|
| Video Recording | 1 | 2013 | 193 | 0.090 |
Why?
|
| Adenine | 1 | 2012 | 110 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2015 | 407 | 0.080 |
Why?
|
| Family Practice | 1 | 2011 | 84 | 0.080 |
Why?
|
| Poisson Distribution | 1 | 2011 | 50 | 0.080 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 31 | 0.080 |
Why?
|
| Rural Health | 1 | 2011 | 46 | 0.080 |
Why?
|
| Niacin | 1 | 2011 | 59 | 0.080 |
Why?
|
| Fenofibrate | 1 | 2011 | 59 | 0.080 |
Why?
|
| Sulfamethizole | 1 | 2010 | 1 | 0.080 |
Why?
|
| Trimethoprim | 1 | 2010 | 3 | 0.080 |
Why?
|
| Dapsone | 1 | 2010 | 5 | 0.080 |
Why?
|
| Genes, pol | 1 | 2010 | 10 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 555 | 0.080 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2010 | 21 | 0.080 |
Why?
|
| Adiponectin | 1 | 2011 | 123 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 151 | 0.080 |
Why?
|
| Anemia, Hemolytic | 1 | 2010 | 30 | 0.080 |
Why?
|
| Safe Sex | 1 | 2010 | 16 | 0.080 |
Why?
|
| Drug Resistance, Viral | 1 | 2010 | 58 | 0.080 |
Why?
|
| Models, Statistical | 1 | 2013 | 483 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 143 | 0.080 |
Why?
|
| Focus Groups | 1 | 2011 | 239 | 0.080 |
Why?
|
| Health Facilities | 1 | 2010 | 66 | 0.080 |
Why?
|
| Disability Evaluation | 1 | 2011 | 191 | 0.080 |
Why?
|
| Viremia | 1 | 2010 | 130 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2010 | 63 | 0.080 |
Why?
|
| Needs Assessment | 1 | 2011 | 173 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 80 | 0.080 |
Why?
|
| Disease Management | 1 | 2013 | 558 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2010 | 270 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 1306 | 0.070 |
Why?
|
| Hepatitis B | 2 | 2008 | 171 | 0.070 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 153 | 0.070 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2009 | 17 | 0.070 |
Why?
|
| Pregnancy | 5 | 2015 | 7512 | 0.070 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2009 | 29 | 0.070 |
Why?
|
| Mental Disorders | 2 | 2025 | 910 | 0.070 |
Why?
|
| Haemophilus Infections | 1 | 2009 | 97 | 0.070 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 134 | 0.070 |
Why?
|
| Research | 1 | 2010 | 264 | 0.070 |
Why?
|
| Physician's Role | 1 | 2010 | 164 | 0.070 |
Why?
|
| Health Resources | 2 | 2014 | 131 | 0.070 |
Why?
|
| Informed Consent | 1 | 2011 | 351 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2009 | 237 | 0.070 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 78 | 0.070 |
Why?
|
| Malawi | 3 | 2015 | 348 | 0.070 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2009 | 66 | 0.070 |
Why?
|
| Cause of Death | 2 | 2014 | 506 | 0.070 |
Why?
|
| Pediatric Obesity | 1 | 2013 | 419 | 0.070 |
Why?
|
| Dyslipidemias | 1 | 2011 | 256 | 0.070 |
Why?
|
| Neoplasms | 2 | 2015 | 3016 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 266 | 0.070 |
Why?
|
| SEER Program | 1 | 2009 | 214 | 0.070 |
Why?
|
| Age Factors | 2 | 2011 | 2825 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2013 | 1211 | 0.070 |
Why?
|
| Hyperglycemia | 1 | 2009 | 234 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2011 | 3061 | 0.070 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2007 | 44 | 0.070 |
Why?
|
| Cryoglobulinemia | 1 | 2007 | 10 | 0.060 |
Why?
|
| Neurocysticercosis | 1 | 2007 | 27 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 567 | 0.060 |
Why?
|
| International Classification of Diseases | 1 | 2007 | 95 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 138 | 0.060 |
Why?
|
| Social Class | 1 | 2008 | 214 | 0.060 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8635 | 0.060 |
Why?
|
| Metabolic Syndrome | 1 | 2010 | 369 | 0.060 |
Why?
|
| Streptococcus pneumoniae | 1 | 2009 | 389 | 0.060 |
Why?
|
| Prejudice | 1 | 2006 | 39 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2006 | 48 | 0.060 |
Why?
|
| Papanicolaou Test | 1 | 2006 | 35 | 0.060 |
Why?
|
| Acute Coronary Syndrome | 1 | 2009 | 235 | 0.060 |
Why?
|
| Pandemics | 2 | 2023 | 1118 | 0.060 |
Why?
|
| Culturally Competent Care | 1 | 2026 | 50 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 1410 | 0.060 |
Why?
|
| Urban Health Services | 1 | 2005 | 15 | 0.060 |
Why?
|
| Genome, Viral | 1 | 2026 | 165 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 895 | 0.050 |
Why?
|
| Asthma | 1 | 2013 | 922 | 0.050 |
Why?
|
| Medical Records | 1 | 2005 | 174 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2005 | 351 | 0.050 |
Why?
|
| San Francisco | 1 | 2004 | 19 | 0.050 |
Why?
|
| Uncompensated Care | 1 | 2004 | 11 | 0.050 |
Why?
|
| Osteomyelitis | 1 | 2007 | 209 | 0.050 |
Why?
|
| Smokers | 1 | 2024 | 48 | 0.050 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2007 | 151 | 0.050 |
Why?
|
| Diketopiperazines | 1 | 2023 | 7 | 0.050 |
Why?
|
| Liver Failure, Acute | 1 | 2005 | 98 | 0.050 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 208 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 281 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 744 | 0.050 |
Why?
|
| Telephone | 1 | 2023 | 111 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2003 | 414 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2003 | 80 | 0.050 |
Why?
|
| Mental Health Services | 1 | 2025 | 285 | 0.050 |
Why?
|
| RNA, Viral | 3 | 2010 | 497 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2003 | 481 | 0.040 |
Why?
|
| Comorbidity | 2 | 2021 | 1595 | 0.040 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 571 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2006 | 394 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2005 | 564 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2006 | 1064 | 0.040 |
Why?
|
| Feedback | 1 | 2022 | 144 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2003 | 323 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 386 | 0.040 |
Why?
|
| Data Collection | 2 | 2013 | 370 | 0.040 |
Why?
|
| Mental Recall | 1 | 2021 | 138 | 0.040 |
Why?
|
| Biomarkers | 2 | 2026 | 3385 | 0.040 |
Why?
|
| Lebanon | 1 | 2020 | 10 | 0.040 |
Why?
|
| Sustained Virologic Response | 1 | 2020 | 46 | 0.040 |
Why?
|
| Patient Navigation | 1 | 2020 | 27 | 0.040 |
Why?
|
| Machine Learning | 1 | 2024 | 387 | 0.040 |
Why?
|
| Pharmacists | 1 | 2020 | 104 | 0.040 |
Why?
|
| Directly Observed Therapy | 1 | 2018 | 25 | 0.040 |
Why?
|
| Software | 1 | 2024 | 733 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2009 | 272 | 0.040 |
Why?
|
| Registries | 2 | 2019 | 1634 | 0.030 |
Why?
|
| Tablets | 1 | 2018 | 37 | 0.030 |
Why?
|
| Health Services Research | 1 | 2019 | 180 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 129 | 0.030 |
Why?
|
| Uganda | 1 | 2017 | 85 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 1680 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 306 | 0.030 |
Why?
|
| Prognosis | 3 | 2012 | 4886 | 0.030 |
Why?
|
| Financial Support | 1 | 2014 | 6 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 179 | 0.030 |
Why?
|
| Health Behavior | 1 | 2018 | 387 | 0.030 |
Why?
|
| District of Columbia | 1 | 2014 | 16 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 2304 | 0.030 |
Why?
|
| Walk Test | 1 | 2014 | 25 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 81 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 164 | 0.030 |
Why?
|
| Premedication | 1 | 2013 | 39 | 0.020 |
Why?
|
| Exanthema | 1 | 2014 | 74 | 0.020 |
Why?
|
| Decision Making | 1 | 2019 | 726 | 0.020 |
Why?
|
| Exercise Test | 1 | 2014 | 239 | 0.020 |
Why?
|
| Standard of Care | 1 | 2014 | 133 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2012 | 71 | 0.020 |
Why?
|
| Mortality | 1 | 2014 | 264 | 0.020 |
Why?
|
| Community Networks | 1 | 2012 | 30 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2013 | 185 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 321 | 0.020 |
Why?
|
| Sleep | 1 | 2013 | 381 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2012 | 345 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2010 | 95 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 202 | 0.020 |
Why?
|
| Health Planning | 1 | 2009 | 16 | 0.020 |
Why?
|
| Alabama | 1 | 2009 | 43 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2009 | 50 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 602 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2010 | 245 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2009 | 197 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 456 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1626 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 239 | 0.020 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2007 | 62 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2007 | 116 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 1071 | 0.010 |
Why?
|
| Rifampin | 1 | 2007 | 128 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 70 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 531 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2009 | 526 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 2006 | 180 | 0.010 |
Why?
|
| Vancomycin | 1 | 2007 | 226 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2005 | 97 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 892 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 716 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 711 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 2595 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 1216 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 422 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1591 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 676 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2003 | 85 | 0.010 |
Why?
|
| Liver | 1 | 2010 | 1796 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 2065 | 0.010 |
Why?
|